Shots:
- Merck has reported ongoing P-III (KEYNOTE-B96/ENGOT-ov65) trial findings on Keytruda for the treatment of Pt-resistant recurrent ovarian cancer
- Trial assessed Keytruda (400mg, IV, Q6W for ~2yrs.) with CT ± Avastin vs PBO + CT ± Avastin in pts (n=643)
- Trial met its 1EP of improved PFS in overall population & 2EP of OS in pts with PD-L1-positive tumors (CPS ≥1) at interim analyses by IDMC; overall OS results to be evaluated in future. Data to be presented at future meeting & shared with global health authorities
Ref: Businesswire | Image: Merck | Press Release
Related News:- Merck’s Welireg Receives the US FDA’s Approval for Pheochromocytoma and Paraganglioma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
